Literature DB >> 10828534

Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.

S Ouary1, N Bizat, S Altairac, H Ménétrat, V Mittoux, F Condé, P Hantraye, E Brouillet.   

Abstract

Chronic systemic treatment with 3-nitropropionic acid in rats produces persistent dystonia and bradykinesia, and striatal lesions reminiscent of Huntington's disease. However, the interpretation of results obtained with this model are complicated by a heterogeneous distribution of the response to a given toxic dose of 3-nitropropionic acid: approximately half of the animals develop selective striatal lesions, which in certain cases are associated with extrastriatal lesions, and the other half are apparently spared. Thus, the chronic 3-nitropropionic acid lesion model can be difficult for neuroprotection studies in which a consistent response to neurotoxic treatment is prerequisite. We hypothesized that some of the variability in the model was related to the use of Sprague-Dawley rats, since inter-individual variability in response to various stressful conditions has been described previously in this rat strain. We therefore compared 3-nitropropionic acid toxicity in rat strains known to be highly (Fisher 344) or poorly (Lewis) responsive to stress and compared the distribution of responses to that of Sprague-Dawley rats. In a protocol of intraperitoneal injection, toxicity of 3-nitropropionic acid was highest in Fisher rats, intermediate in Sprague-Dawley rats and lowest in Lewis rats. In addition, survival curves showed a more heterogeneous response to 3-nitropropionic acid toxicity in Sprague-Dawley rats than that observed in Lewis and Fisher rats. These differences between Sprague-Dawley and Lewis rats were confirmed in a protocol of subcutaneous 3-nitropropionic acid intoxication using osmotic minipumps, where doses up to 36-45mg/kg per day for five days were necessary to induce striatal lesions in Lewis rats as compared to 12-14mg/kg per day for five days in Sprague-Dawley rats. The selectivity of the striatum to lesions, and homogeneous progression of symptoms and neurodegeneration, were more consistently observed in Lewis as compared to Sprague-Dawley rats. These results suggest that vulnerability to 3-nitropropionic acid may depend on genetic factors, which could also influence the physiological response to stress. The present findings also establish an improved model of progressive striatal degeneration in the rat adapted for the testing of new neuroprotective strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828534     DOI: 10.1016/s0306-4522(00)00020-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  28 in total

1.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

2.  Behavioral alterations in Lewis rats following two-day continuous 3-nitropropionic acid administration.

Authors:  J D Newcomb; W D Brown; A I Rodriguez; S Garbuzova-Davis; S Saporta; P R Sanberg; A E Willing
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

3.  Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.

Authors:  Garnik Akopian; Cynthia Crawford; M Flint Beal; Maurand Cappelletti; Michael W Jakowec; Giselle M Petzinger; Ling Zheng; Stacey L Gheorghe; Carmela M Reichel; Robert Chow; John P Walsh
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

4.  The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.

Authors:  David Blum; David Gall; Marie-Christine Galas; Pablo d'Alcantara; Kadiombo Bantubungi; Serge N Schiffmann
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

5.  Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat.

Authors:  G Akopian; C Crawford; G Petzinger; M W Jakowec; J P Walsh
Journal:  Neuroscience       Date:  2012-04-30       Impact factor: 3.590

6.  No spatial memory deficit exists in Kunming mice that recently recovered from motor defects following 3-nitropropionic acid intoxication.

Authors:  Xiao-Min Li; Bing-Gen Zhu; Jian-Bo Ni; Chun-Yan Cao; Jie-Ping Zhang; Xu-Dong Zhao; Rong-Shen Zhu
Journal:  Neurosci Bull       Date:  2009-04       Impact factor: 5.203

7.  N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity.

Authors:  Payman Nasr; Timothy Carbery; James W Geddes
Journal:  Neurochem Res       Date:  2008-08-08       Impact factor: 3.996

8.  Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice.

Authors:  William F Maragos; Kristie L Young; Chris S Altman; Chava B Pocernich; Jennifer Drake; D Allan Butterfield; Isabelle Seif; Daniel P Holschneider; Kevin Chen; Jean C Shih
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

9.  Promethazine protects against 3-nitropropionic acid-induced neurotoxicity.

Authors:  Carine Cleren; Noel Y Calingasan; Anatoly Starkov; Carine Jacquard; Junya Chen; Emmanuel Brouillet; M Flint Beal
Journal:  Neurochem Int       Date:  2009-10-21       Impact factor: 3.921

10.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.

Authors:  William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.